While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 ...

UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...

BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative ...

While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers. Moderna’s share price rose ...

Eli Lilly joins hands with Engage Bio, acquiring the DNA delivery platform developer in hopes of bolstering its genetic medicines portfolio. Buoyed by its weight-loss windfall, Eli Lilly is continuing ...

While the manufacturer is on the list of authorized GLP-1 importers, FDA inspectors found the company relabeled APIs from another site in a potential attempt to “circumvent safeguards.” A Chinese ...

FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency’s two main review units also left their posts, as did the FDA ...

Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology ...

Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular ...

Far fewer companies are letting employees go so far in 2026 compared to 2025, but the number of people affected is trending ...

Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...

Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a ...